Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 151-158 , May 2011

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

  • Fredrick L. Dunn

      Affiliations

    • University of Texas Southwestern Medical Center, Dallas, TX, USA
    • Corresponding Author InformationCorresponding author. Center for Human Nutrition, University of Texas Southwestern, Dallas, TX 75230-9052, USA.
    • ,
  • Linda S. Higgins

      Affiliations

    • InteKrin Therapeutics Inc., Los Altos, CA, USA
    • ,
  • Jill Fredrickson

      Affiliations

    • Pharsight Corporation, Mountain View, CA, USA
    • ,
  • Alex M. DePaoli

      Affiliations

    • InteKrin Therapeutics Inc., Los Altos, CA, USA
    • ,
  • for the INT131-004 study group

Received 17 March 2010 ,Revised 21 June 2010 ,Accepted 30 June 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Clinical Trial Registration: NCT00952445.

☆☆ Disclosures: Dr. Dunn is a member of the Scientific Advisory Board of InteKrin Therapeutics Inc. Drs Higgins and DePaoli are employees of InteKrin Therapeutics. Dr. Fredrickson was previously employed by Pharsight.

PII: S1056-8727(10)00071-1

doi: 10.1016/j.jdiacomp.2010.06.006

Journal of Diabetes and Its Complications
Volume 25, Issue 3 , Pages 151-158 , May 2011

Article Tools

* Image Usage & Resolution